Neuromuscular Disorders

📚 02 Pediatric Superspecialities • 🎯 64 High-Yield MCQs • Nelson 22nd Edition Standard

Pediatric Neuromuscular Disorders & Channelopathies

  • Nerve Conduction Velocity (NCV) Maturation: ((NMD001)): At birth, NCV is approximately 50% of adult values due to incomplete myelination; mature values are typically reached by 2 years of age (not 3 years). NCV studies measure only the fastest conducting fibers.
  • Duchenne Muscular Dystrophy (DMD) Therapeutics: ((NMD002)): Golodirsen (and viltolarsen) are antisense oligonucleotides (ASOs) designed for exon 53 skipping, restoring partially functional dystrophin. Eteplirsen targets exon 51.
  • Vitamin E Myopathy: ((NMD003)): Vitamin E ($\alpha$-tocopherol) deficiency AND chronic hypervitaminosis both cause myopathy (associated with progressive proximal weakness, hyporeflexia, and ataxia).
  • Paramyotonia Congenita: ((NMD004)): A non-dystrophic myotonia caused by sodium channel ($SCN4A$) mutations characterized by paradoxical worsening of stiffness with repeated activity and cold exposure (unlike classic myotonia congenita where warm-up relieves stiffness).
  • Charcot-Marie-Tooth (CMT) Disease Classification: ((((NMD005)) · ((NMD006)) · ((NMD027)))):
  • CMT1 / CMT3: (Demyelinating): Associated with PMP22 gene duplications (causing Schwann cell dysfunction and tomaculous neuropathy/HNPP). NCV is markedly reduced.
  • CMT2: (Axonal): Associated with MFN2 (mitofusin) mutations. NCV is relatively preserved with reduced amplitudes.
  • Spinal Muscular Atrophy (SMA) Type 1: ((NMD007)): Autosomal recessive homozygous deletion of SMN1 (chromosome 5q). Presents with progressive hypotonia, weak cry/cough, tongue fasciculations, and absent deep tendon reflexes with preserved sensation. Nusinersen is a first-line disease-modifying therapy.
  • Transient Neonatal Myasthenia Gravis (TNMG): ((NMD008)): Affects 10–20% of infants born to mothers with myasthenia gravis via transplacental transfer of maternal IgG autoantibodies. Presents in the first 1–3 days of life with hypotonia, poor feeding, and weak cry; it is self-limiting within weeks as maternal antibodies clear.
  • Hypokalemic Periodic Paralysis: ((NMD009)): Caused by mutations in calcium, sodium, or potassium voltage-gated ion channels leading to episodic flaccid weakness (precipitated by rest after exercise or high-carbohydrate meals) with low serum potassium during attacks.
  • Duchenne Muscular Dystrophy (DMD) Clinical Pearls: ((((NMD010)) · ((NMD017)) · ((NMD020)))): - Caused by out-of-frame $DMD$ gene mutations (Xp21) leading to absent dystrophin and markedly elevated CK. - Knee reflexes are typically lost earlier than ankle reflexes. - Associated with dilated cardiomyopathy (as are Becker and Emery-Dreifuss MD; note that Friedreich ataxia causes hypertrophic cardiomyopathy). - Approximately 30% of cases are de novo mutations; maternal carrier status is confirmed via blood DNA analysis, and chorionic villus sampling (CVS) enables prenatal diagnosis by 12 weeks.
  • Andersen-Tawil Syndrome: ((NMD011)): Autosomal dominant KCNJ2 mutations causing the classic triad of periodic paralysis, ventricular arrhythmias (prolonged QU interval, prominent U waves), and distinctive dysmorphic features (low-set ears, micrognathia, clinodactyly).
  • Emery-Dreifuss Muscular Dystrophy (EDMD): ((NMD012)): Characterized by the classic triad of early joint contractures (elbows, Achilles tendons, posterior neck), humeroperoneal muscle weakness, and cardiac conduction abnormalities.
  • Brown-Vialetto-Van Laere (BVVL) Syndrome: ((NMD013)): A riboflavin transporter deficiency caused by mutations in SLC52A2 or SLC52A3, presenting with pontobulbar palsy, sensorineural deafness, and motor neuron disease–like features with diaphragmatic weakness.
  • Myasthenia Gravis Electromyography: ((NMD014)): Hallmark is a decremental CMAP response (>10% drop between 1st and 4th response) on low-frequency (2–3 Hz) repetitive nerve stimulation.
  • Congenital Myasthenic Syndromes (CMS): ((((NMD015)) · ((NMD026)) · ((NMD029)))):
  • COLQ Mutation: (Synaptic): Causes end-plate acetylcholinesterase deficiency. Paradoxically worsens with acetylcholinesterase inhibitors (e.g., pyridostigmine) due to acetylcholine persistence and prolonged depolarization.
  • CHAT Mutation: (Presynaptic): Choline acetyltransferase deficiency presenting with neonatal weakness and characteristic episodic apnea with respiratory crises.
  • Non-Neuromuscular CK Elevation: ((NMD016)): Hypothyroidism is a recognized endocrine cause of elevated creatine kinase and proximal myalgia/weakness, mimicking primary myopathy.
  • Congenital Myopathies: ((((NMD018)) · ((NMD028)) · ((NMD030)))):
  • Myotubular/Centronuclear Myopathy: : Severe neonatal hypotonia, facial weakness, ptosis, and extraocular muscle weakness; biopsy shows numerous centrally placed nuclei in small fibers.
  • Central Core Disease: : Caused by RYR1 mutations leading to abnormal calcium release; muscle biopsy shows central cores with absent oxidative enzyme activity.
  • Ullrich Congenital Muscular Dystrophy: : Caused by COL6A1/COL6A2 mutations; features severe hypotonia, proximal contractures with distal joint hyperlaxity, respiratory insufficiency, keratosis pilaris, and the muscle MRI “central cloud” sign in the rectus femoris.
  • Myofibrillar Myopathy: ((NMD019)): Protein aggregate myopathies showing Z-disc disintegration; experimental therapies include 4-phenylbutyrate as an antiaggregation agent.
  • Toxic Myopathies & Rhabdomyolysis: ((NMD021)): Statins are classically implicated in toxic necrotizing vacuolar myopathy and acute rhabdomyolysis presenting with myalgia, dark urine (myoglobinuria), and markedly elevated CK.
  • Toxic Neuropathies: ((NMD022)): Recognized metal causes include arsenic, lead, gold, lithium, mercury, thallium, and zinc. Cobalt is not a classic cause in this classification.
  • Miller Fisher Syndrome: ((NMD023)): A Guillain-Barré variant defined by the triad of ophthalmoplegia, ataxia, and areflexia, highly specific for anti-GQ1b antibodies (whereas anti-GM1 targets axonal GBS/AMAN).
  • Myotonic Dystrophy Type 1 (DM1): ((NMD024)): Caused by CTG trinucleotide repeat expansion in the DMPK gene (chromosome 19q13.3). Congenital/infantile forms present with severe hypotonia, facial diplegia (downturned "tented" mouth), and delayed milestones, but myotonia is characteristically absent in infancy.
  • Facioscapulohumeral Muscular Dystrophy (FSHD): ((NMD025)): Caused by contraction of D4Z4 macrosatellite repeats on chromosome 4q35 (DUX4 overexpression). Features facial diplegia, scapular winging, and asymmetric upper arm weakness (sparing the deltoids); associated with Coats retinopathy and sensorineural hearing loss, but cardiomyopathy is atypical.
  • McArdle Disease (GSD V): ((NMD031)): Caused by deficiency of muscle glycogen phosphorylase (PYGM gene, chromosome 11q13), presenting during exercise with cramps, pain, and tea-colored urine (myoglobinuria).
  • Guillain-Barré Syndrome (GBS): ((NMD032)): Ascending symmetrical flaccid paralysis with areflexia, demyelinating features on nerve conduction studies, and CSF albuminocytologic dissociation (elevated protein with normal cell count). Early IVIG reduces respiratory failure risk.
  • Alpha-Dystroglycanopathies: ((NMD033)): Congenital muscular dystrophies featuring marked CK elevation and unique central nervous system malformations (lissencephaly, pachygyria, white matter changes).
  • Lower Motor Neuron Localization: ((NMD034)): Marked weakness with hypotonia, reduced reflexes, preserved sensation, and visible tongue fasciculations localizes the lesion to the anterior horn cell / alpha motor neuron (e.g., SMA).
  • Acute Flaccid Myelitis (AFM): ((NMD035)): Poliomyelitis-like lower motor neuron syndrome following a viral prodrome, characterized by asymmetric flaccid weakness (arms more than legs), reduced tone/reflexes, preserved sensation, and no sensory level or bladder dysfunction.

Congenital Myopathies & Muscular Dystrophies

  • Congenital Muscle Fiber-Type Disproportion (CMFTD): ((NMD036)): May occur as an isolated, nonprogressive/slowly progressive congenital myopathy or as part of a syndrome associated with Krabbe disease (Option A). Infants show generalized hypotonia, weakness, poor head control, dolichocephaly, facial weakness, and high-arched palate; CK, ECG, and EMG are typically normal. (Note: Wilson disease, Tay-Sachs, and Lesch-Nyhan are not classically associated).
  • Proteus Syndrome: ((NMD037)): Disorder of cellular overgrowth from postzygotic somatic mosaicism involving AKT1 (Option A) (mTOR pathway). Characterized by asymmetric limb overgrowth, verrucous cutaneous lesions, angiomas, thickened bones, excessive muscle growth without true weakness, and hemimegalencephaly.
  • Distal Arthrogryposis: ((NMD038)): Characterized by congenital contractures predominantly in distal limbs (hands and feet) with spared proximal joints. Features include camptodactyly, hypoplastic flexion creases, overriding fingers, ulnar deviation, and talipes equinovarus, occurring without primary neurologic or muscle disease.
  • Barth Syndrome: ((((NMD039)) · ((NMD059)))): X-linked disorder due to TAFAZZIN (TAZ) mutations presenting with infantile hypotonia, delayed motor milestones, cardiomyopathy (left ventricular non-compaction), neutropenia (recurrent bacterial infections), skeletal myopathy, and persistently elevated urinary 3-methylglutaconic acid (Option C).
  • SEPN1-Related Myopathy (Rigid Spine Syndrome): ((NMD060)): Caused by mutations in SEPN1 (Selenoprotein N) (Option B). Presents with early infantile hypotonia, independent walking by ~2 years, fatigue, sleep-disordered breathing, axial hypotonia, lumbar lordosis, narrow bell-shaped chest, and progressive spinal rigidity (inability to flex the spine forward), with preserved facial/limb strength.
  • Nemaline Myopathy: ((NMD061)): Congenital myopathy most commonly caused by mutations in NEB (Nebulin) (Option B). Muscle biopsy shows small, spindle-shaped rod-like eosinophilic inclusions (nemaline bodies) on modified Gomori trichrome stain and Z-disk continuities on electron microscopy.
  • Collagen VI-Related Myopathies (Ullrich CMD / Bethlem Myopathy): ((NMD062)): Caused by COL6A1, COL6A2 (Option A), or COL6A3 mutations. Features severe neonatal hypotonia, proximal joint contractures, distal joint hyperlaxity, and respiratory compromise. Muscle MRI demonstrates an "outside-in" pattern (central vastus lateralis sparing with peripheral increased signal) and "central cloud" in the rectus femoris.

Hereditary Motor, Sensory, & Autonomic Neuropathies

  • Andersen Syndrome (Type 7 Periodic Paralysis): ((NMD039)): Dominantly inherited channelopathy presenting with episodic flaccid weakness (provoked by rest after exercise or glucose) combined with short stature, dysmorphic features, prolonged QT interval, and ventricular dysrhythmias (Option C). Myotonia is absent.
  • Refsum Disease: ((NMD044)): Autosomal recessive disorder of phytanic acid metabolism caused by PHYH or PEX7 mutations (Option A). Features childhood-onset motor/sensory neuropathy, ataxia, retinitis pigmentosa (night blindness), sensorineural hearing loss, ichthyosis, pes cavus, cardiomyopathy/conduction abnormalities, hepatomegaly, and CSF albuminocytologic dissociation (elevated protein without pleocytosis). Diet is rich in branched-chain fatty acids.
  • Roussy-Lévy Syndrome: ((NMD045)): Combination of hereditary motor and sensory neuropathy type II and cerebellar deficits (Friedreich-like ataxia) with pes cavus. Cardiomyopathy is not a feature (Option D).
  • CMT1 Plus: ((NMD046)): Demyelinating HMSN associated with syndromic features like macular degeneration and cutis laxa, linked to FBLN5 (Option D) (contrasting with standard CMT1A caused by PMP22 duplication).
  • Hereditary Sensory and Autonomic Neuropathy Type I (HSAN-I): ((NMD047)): Autosomal dominant disorder caused by SPTLC1 mutations in the sphingolipid pathway (Option C). Presents in late adolescence/young adulthood with painless injuries over feet/tongue, Charcot joints, absent reflexes, loss of corneal reflex with recurrent abrasions, deafness, and proprioceptive/thermal sensory loss.
  • HSAN-III (Familial Dysautonomia / Riley-Day Syndrome): ((NMD048)): Autosomal recessive disorder due to mutations in IKBKAP/ELP1 (Option C). Presents in infancy with severe autonomic dysfunction: defective tears (alacrima), recurrent fevers, feeding difficulties, postural hypotension, hyperhidrosis, diminished reflexes, and thermal insensitivity.
  • Interstitial Hypertrophic Neuropathy: ((NMD064)): Sural nerve biopsy shows onion bulb formations (concentric Schwann cell proliferation around axons reflecting repeated segmental demyelination/remyelination) pathognomonic for demyelinating hereditary motor and sensory neuropathies like Charcot-Marie-Tooth disease (Option B).

Neuromuscular Transmission Disorders & Toxic Neuropathies

  • Efgartigimod: ((NMD040)): Neonatal Fc receptor antagonist that blocks FcRn-mediated IgG recycling, accelerating IgG breakdown and lowering pathogenic antibodies (e.g., anti-AChR) in severe generalized myasthenia gravis (Option B). (Rituximab depletes CD20 B-cells; eculizumab inhibits C5).
  • Myasthenia Gravis Drug Precautions: ((NMD041)): Avoid antibiotics that impair neuromuscular transmission, notably aminoglycosides and fluoroquinolones (e.g., Levofloxacin) (Option C), as well as $\beta$-blockers, procainamide, and chloroquine. Succinylcholine and pancuronium cause prolonged paralysis.
  • Linezolid Toxicity: ((NMD049)): Dose-dependent toxic peripheral neuropathy, classically presenting as a painful, predominantly sensory, axonal neuropathy (distal paresthesias and burning pain) and optic neuropathy following prolonged therapy (Option B).
  • Vincristine Neuropathy: ((NMD050)): Chemotherapy-induced peripheral neuropathy causing distal weakness, sensory symptoms, and prominent autonomic involvement (constipation, ileus) (Option C). (Cisplatin causes pure sensory neuropathy; paclitaxel and bortezomib have distinct profiles).

Spinal Muscular Atrophy (SMA) & Channelopathies

  • SMA Type I (Werdnig-Hoffmann Disease): ((NMD042)): Presents before 6 months with severe hypotonia, poor head control, symmetric generalized weakness (lower > upper limbs, proximal > distal), frog-leg posture, absent DTRs, tongue fasciculations, and paradoxical abdominal breathing (diaphragmatic sparing with intercostal weakness) alongside an alert, bright facies (Option A).
  • Onasemnogene Abeparvovec-Xioi: ((NMD043)): AAV9-mediated gene replacement therapy for SMA type I delivering functional SMN1. Requires systemic corticosteroids (prednisolone) starting the day before treatment and tapered over 3–4 months to manage anticipated immune-mediated hepatitis with ALT/AST elevation (Option B).
  • Schwartz-Jampel Syndrome: ((NMD063)): Autosomal recessive disorder caused by HSPG2 mutations (perlecan deficiency). Presents with progressive myotonia, muscle hypertrophy, joint contractures, short stature, and facial dysmorphism (blepharophimosis, micrognathia). First-line treatment for myotonic symptoms is sodium channel blockers like Carbamazepine (Option A).

Guillain-Barré Syndrome, CIDP, & Cranial Neuropathies

  • Guillain-Barré Syndrome (GBS) CSF Profile: ((NMD053)): Characterized by albuminocytologic dissociation (elevated protein with normal cell count). A CSF polymorphonuclear or mononuclear cell count >50 cells/µL (Option C) strongly disputes GBS and demands evaluation for alternate infectious/inflammatory etiologies.
  • Bickerstaff Brainstem Encephalitis: ((NMD054)): CNS variant within the GBS/Miller Fisher spectrum presenting with ophthalmoplegia, ataxia, and altered sensorium/drowsiness with minimal limb weakness and anti-GQ1b/GT1a antibodies (Option C).
  • GBS Prognosis & Long-Term Sequelae: ((((NMD055)) · ((NMD056)))): IVIG hastens acute recovery but does not alter long-term neurological outcome. Demyelination forms recover faster than axonal forms. Fatigue is the most common long-term residuum (Option A), while persistent focal weakness most frequently involves ankle dorsiflexors.
  • Acute-Onset CIDP vs. GBS: ((NMD052)): Suspect Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) when weakness/paresthesias progress beyond 4–6 weeks, recur intermittently, or show a fluctuating course ("good and bad weeks"). Treatment options include either repeat IVIG or corticosteroids (Option C).
  • Lyme-Associated Facial Palsy: ((NMD057)): Unilateral or bilateral LMN facial nerve palsy preceded by systemic constitutional symptoms (fever, malaise, headache, body aches) should raise suspicion for Lyme disease in endemic regions, distinguishing it from idiopathic Bell palsy (Option B).
  • Bell Palsy Management: ((NMD058)): Pediatric Bell palsy carries an excellent prognosis. The single most crucial acute management step is corneal protection with ocular lubricants (Option B) to prevent exposure keratitis due to incomplete eye closure.

Autonomic Function Testing

  • Quantitative Sudomotor Axon Reflex Test (QSART): ((NMD051)): Assesses sympathetic cholinergic function (sweat pathways/sudomotor activity) (Option C). (Deep respiration heart rate variability tests cardiac parasympathetic function; blood pressure response to posture tests vasomotor adrenergic function).